Role of chemotherapy in the management of soft tissue sarcomas

Expert Review of Anticancer Therapy

Volumn 10, Issue 2, 2010, Pages 249-260

  Krikelis, Dimitrios ^a   Judson, Ian ^b  

^a UNIVERSITY HOSPITAL OF IOANNINA   (Greece)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Adjuvant; Chemotherapy; Curative; Docetaxel; Doxorubicin; Gemcitabine; Ifosfamide; Neoadjuvant; Palliative; Trabectedin

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACARBAZINE; DACTINOMYCIN; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MELPHALAN; MESNA; PACLITAXEL; TAXANE DERIVATIVE; TRABECTEDIN; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; ALOPECIA; AMINOTRANSFERASE BLOOD LEVEL; ANGIOSARCOMA; BONE MARROW TOXICITY; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; DOSAGE SCHEDULE COMPARISON; DOSE RESPONSE; DRUG DNA BINDING; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG MEGADOSE; EWING SARCOMA; HISTOLOGY; HUMAN; LEIOMYOSARCOMA; LIPOSARCOMA; LIVER FUNCTION; LIVER TOXICITY; LOW DRUG DOSE; MEDICAL DECISION MAKING; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYXOSARCOMA; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; OVERALL SURVIVAL; RECOMMENDED DRUG DOSE; REVIEW; RHABDOMYOLYSIS; RHABDOMYOSARCOMA; SIDE EFFECT; SOFT TISSUE SARCOMA; SURVIVAL; SYNOVIAL SARCOMA; THROMBOCYTOPENIA; UNSPECIFIED SIDE EFFECT;

ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; HUMANS; SARCOMA;

EID: 76749117217     PISSN: 14737140     EISSN: 17448328     Source Type: Journal    
DOI: 10.1586/ERA.09.176     Document Type: Review

References (105)

1. Karavasilis V, Seddon BM, Ashley S, Al-Muderis O, Fisher C, Judson I. Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients. Cancer 112, 1585-1591 (2008). •• Systematic evaluation of the role of first-line palliative chemotherapy in soft tissue sarcoma (STS).
2. Borden EC, Amato DA, Rosenbaum C et al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J. Clin. Oncol. 5, 840-850 (1987).
3. Judson I, Radford JA, Harris M et al. Randomised Phase II trial of pegylated liposomal doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer 37, 870-877 (2001).
4. Santoro A, Tursz T, Mouridsen H et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J. Clin. Oncol. 13, 1537-1545 (1995).
5. Edmonson JH, Ryan LM, Blum RH et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J. Clin. Oncol. 11, 1269-1275 (1993).
6. Borden EC, Amato DA, Edmonson JH, Ritch PS, Shiraki M. Randomized comparison of doxorubicin and vindesine to doxorubicin for patients with metastatic soft-tissue sarcomas. Cancer 66, 862-867 (1990).
7. van Oosterom AT, Mouridsen HT, Nielsen OS et al. Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and secondline chemotherapy in advanced soft tissue sarcoma patients. Eur. J. Cancer 38, 2397-2406 (2002). • First demonstration of the value of high-dose ifosfamide regimen in the treatment of STS.
8. Schoenfeld DA, Rosenbaum C, Horton J, Wolter JM, Falkson G, DeConti RC. A comparison of adriamycin versus vincristine and adriamycin, and cyclophosphamide versus vincristine, actinomycin-D, and cyclophosphamide for advanced sarcoma. Cancer 50, 2757-2762 (1982).
9. Antman K, Crowley J, Balcerzak SP et al. An intergroup Phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J. Clin. Oncol. 11, 1276-1285 (1993).
10. Zalupski M, Metch B, Balcerzak S et al. Phase III comparison of doxorubicin and dacarbazine given by bolus versus infusion in patients with soft-tissue sarcomas: a Southwest Oncology Group study. J. Natl Cancer Inst. 83, 926-932 (1991).
11. Maurel J, Lopez-Pousa A, de Las Penas R et al. Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized Phase II study of the Spanish group for research on sarcomas. J. Clin. Oncol. 27, 1893-1898 (2009).
12. Reichardt P. High-dose chemotherapy in adult soft tissue sarcoma. Crit. Rev. Oncol. Hematol. 41, 157-167 (2002).
13. Balcerzak SP, Benedetti J, Weiss GR, Natale RB. A Phase II trial of paclitaxel in patients with advanced soft tissue sarcomas. A Southwest Oncology Group study. Cancer 76, 2248-2252 (1995).
14. Patel SR, Linke KA, Burgess MA et al. Phase II study of paclitaxel in patients with soft tissue sarcomas. Sarcoma 1, 95-97 (1997).
15. Verweij J, Lee SM, Ruka W et al. Randomized Phase II study of docetaxel versus doxorubicin in first- and second-line chemotherapy for locally advanced or metastatic soft tissue sarcomas in adults: a study of the european organization for research and treatment of cancer soft tissue and bone sarcoma group. J. Clin. Oncol. 18, 2081-2086 (2000).
16. Fata F, O'Reilly E, Ilson D et al. Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 86, 2034-2037 (1999). • Initial report of paclitaxel activity in scalp or face angiosarcoma.
17. Skubitz KM, Haddad PA. Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer 104, 361-366 (2005).
18. Nagano T, Yamada Y, Ikeda T, Kanki H, Kamo T, Nishigori C. Docetaxel: a therapeutic option in the treatment of cutaneous angiosarcoma: report of 9 patients. Cancer 110, 648-651 (2007).
19. Penel N, Bui BN, Bay JO et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J. Clin. Oncol. 26, 5269-5274 (2008).
20. Schlemmer M, Reichardt P, Verweij J et al. Paclitaxel in patients with advanced angiosarcomas of soft tissue: a retrospective study of the EORTC soft tissue and bone sarcoma group. Eur. J. Cancer 44, 2433-2436 (2008).
21. Fury MG, Antonescu CR, Van Zee KJ, Brennan MF, Maki RG. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J. 11, 241-247 (2005).
22. Hofmann UB, Wobser M, Kneitz H et al. Major response to paclitaxel combined with irradiation as second-line therapy in metastatic angiosarcoma of the face and scalp. Br. J. Dermatol. 160, 456-458 (2009).
23. Gabizon A, Shmeeda H, Barenholz Y. Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin. Pharmacokinet. 42, 419-436 (2003).
24. Eiling S, Lischner S, Busch JO, Rothaupt D, Christophers E, Hauschild A. Complete remission of a radio-resistant cutaneous angiosarcoma of the scalp by systemic treatment with liposomal doxorubicin. Br. J. Dermatol. 147, 150-153 (2002).
25. Lankester KJ, Brown RS, Spittle MF. Complete resolution of angiosarcoma of the scalp with liposomal daunorubicin and radiotherapy. Clin. Oncol. (R. Coll. Radiol.) 11, 208-210 (1999).
26. Holloway CL, Turner AR, Dundas GS. Cutaneous angiosarcoma of the scalp: a case report of sustained complete response following liposomal doxorubicin and radiation therapy. Sarcoma 9, 29-31 (2005).
27. Voss A, Seitz CS, Rose C, Brocker EB, Goebeler M. Successful treatment of angiosarcoma with liposomal-encapsulated doxorubicin. Hautarzt. 52, 895-898 (2001).
28. Wollina U, Fuller J, Graefe T, Kaatz M, Lopatta E. Angiosarcoma of the scalp: treatment with liposomal doxorubicin and radiotherapy. J. Cancer Res. Clin. Oncol. 127, 396-399 (2001).
29. Ferraresi V, Ciccarese M, Cercato MC et al. Gemcitabine at fixed dose-rate in patients with advanced soft-tissue sarcomas: a mono-institutional Phase II study. Cancer Chemother. Pharmacol. 63, 149-155 (2008).
30. Okuno S, Ryan LM, Edmonson JH, Priebat DA, Blum RH. Phase II trial of gemcitabine in patients with advanced sarcomas (E1797): a trial of the Eastern Cooperative Oncology Group. Cancer 97, 1969-1973 (2003).
31. Von BG, Rankin C, Zalupski MM, Mills GM, Borden EC, Karen A. Phase II trial of gemcitabine as first line chemotherapy in patients with metastatic or unresectable soft tissue sarcoma. Am. J. Clin. Oncol. 29, 59-61 (2006).
32. Patel SR, Gandhi V, Jenkins J et al. Phase II clinical investigation of gemcitabine in advanced soft tissue sarcomas and window evaluation of dose rate on gemcitabine triphosphate accumulation. J. Clin. Oncol. 19, 3483-3489 (2001).
33. Hensley ML, Maki R, Venkatraman E et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a Phase II trial. J. Clin. Oncol. 20, 2824-2831 (2002). • Initial report of gemcitabine and docetaxel combination activity in patients with unresectable leiomyosarcoma.
34. Hensley ML, Blessing JA, Mannel R, Rose PG. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group Phase II trial. Gynecol. Oncol. 109, 329-334 (2008).
35. Fleming G. Gemcitabine/docetaxel - welcome to a new standard. Gynecol. Oncol. 109, 313-315 (2008).
36. Hensley ML, Blessing JA, Degeest K, Abulafia O, Rose PG, Homesley HD. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group Phase II study. Gynecol. Oncol. 109, 323-328 (2008).
37. Maki RG, Wathen JK, Patel SR et al. Randomized Phase II Study of Gemcitabine and Docetaxel Compared With Gemcitabine Alone in Patients With Metastatic Soft Tissue Sarcomas: results of Sarcoma Alliance for Research Through Collaboration Study 002. J. Clin. Oncol. 35, 2755-2763 (2007).
38. Pautier P, Bui Nguyen B, Penel N et al. Final results of a FNCLCC French Sarcoma Group multicenter randomized Phase II study of gemcitabine (G) versus gemcitabine and docetaxel (G+D) in patients with metastatic or relapsed leiomyosarcoma (LMS). Presented at: ASCO Annual Meeting. Orlando, FL, USA, 29 May-2 June 2009.
39. Spurrell EL, Fisher C, Thomas JM, Judson IR. Prognostic factors in advanced synovial sarcoma: an analysis of 104 patients treated at the Royal Marsden Hospital. Ann. Oncol. 16, 437-444 (2005).
40. Bokemeyer C, Franzke A, Hartmann JT et al. A Phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas. Cancer 80, 1221-1227 (1997).
41. Carter NJ, Keam SJ. Trabectedin: a review of its use in the management of soft tissue sarcoma and ovarian cancer. Drugs 67, 2257-2276 (2007).
42. Herrero AB, Martin-Castellanos C, Marco E, Gago F, Moreno S. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res. 66, 8155-8162 (2006).
43. Schoffski P, Casali PG, Taron M et al. DNA repair functionality modulates the clinical outcome of patients with advanced sarcoma treated with trabectedin (ET-743). Proc. Am. Soc. Clin. Oncol. 24, (2006) (Abstract 9522).
44. Grosso F, Jones RL, Demetri GD et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol. 8, 595-602 (2007).
45. Yovine A, Riofrio M, Blay JY et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J. Clin. Oncol. 22, 890-899 (2004).
46. Le Cesna A, Blay JY, Judson I et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J. Clin. Oncol. 23, 576-584 (2005). • First report of trabectedin activity against leiomyosarcoma and synovial sarcoma.
47. Garcia-Carbonero R, Supko JG, Manola J et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J. Clin. Oncol. 22, 1480-1490 (2004).
48. van Glabbeke M, Verweij J, Judson I, Nielsen OS. Progression-free rate as the principal end-point for Phase II trials in soft-tissue sarcomas. Eur. J. Cancer 38, 543-549 (2002).
49. Grosso F, Sanfilippo R, Virdis E et al. Trabectedin in myxoid liposarcomas (MLS): a long-term analysis of a singleinstitution series. Ann. Oncol. 20, 1439-1444 (2009).
50. Demetri GD, Chawla SP, von Mehren M et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized Phase II study of two different schedules. J. Clin. Oncol. 27, 4188-4196 (2009).
51. Boudou L, Baconnier M, Blay JY, Lombard-Bohas C, Cassier PA. Trabectedin for the management of soft-tissue sarcoma. Expert. Rev. Anticancer Ther. 9(6), 727-737 (2009).
52. Garcia-Carbonero R, Supko JG, Maki RG et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter Phase II and pharmacokinetic study. J. Clin. Oncol. 23, 5484-5492 (2005).
53. Delaney TF, Yang JC, Glatstein E. Adjuvant therapy for adult patients with soft tissue sarcomas. Oncology (Williston Park) 5, 105-118 (1991).
54. Antman KH. Adjuvant therapy of sarcomas of soft tissue. Semin. Oncol. 24, 556-560 (1997).
55. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet 350, 1647-1654 (1997). •• Most reliable meta-analysis evaluating the role of first-generation adjuvant chemotherapy regimens in the treatment of STS.
56. Adjuvant chemotherapy for localised resectable soft tissue sarcoma in adults. Cochrane Database. Syst. Rev. CD001419 (2000).
57. Frustaci S, Gherlinzoni F, De Paoli A et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J. Clin. Oncol. 19, 1238-1247 (2001).
58. Frustaci S, De Paoli A, Bidoli E et al. Ifosfamide in the adjuvant therapy of soft tissue sarcomas. Oncology 65(Suppl. 2), 80-84 (2003).
59. Petrioli R, Coratti A, Correale P et al. Adjuvant epirubicin with or without ifosfamide for adult soft-tissue sarcoma. Am. J. Clin. Oncol. 25, 468-473 (2002).
60. Brodowicz T, Schwameis E, Widder J et al. Intensified adjuvant IFADIC chemotherapy for adult soft tissue sarcoma: a prospective randomized feasibility trial. Sarcoma 4, 151-160 (2000).
61. Woll J, van Glabbeke M, Hohenberger P et al. Adjuvant chemotherapy (CT) with doxorubicin and ifosfamide in resected soft tissue sarcoma (STS): interim analysis of a randomised Phase III trial. J. Clin. Oncol. 25, (2007).
62. Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 113, 573-581 (2008). •• Meta-analysis evaluating the role of first-and second-generation adjuvant chemotherapy regimens in the treatment of STS.
63. Tierney JF, Mosseri V, Stewart LA, Souhami RL, Parmar MK. Adjuvant chemotherapy for soft-tissue sarcoma: review and meta-analysis of the published results of randomised clinical trials. Br. J. Cancer 72, 469-475 (1995).
64. Le Cesne A, Van Glabbeke M, Woll P. The end of adjuvant chemotherapy era with doxorubicin-based regimen in resected high-grade soft tissue sarcoma: pooled analysis of the two STBSG-EORTC Phase III clinical trials. J. Clin. Oncol. 26, (2008).
65. Bramwell V, Rouesse J, Steward W et al. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma - reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J. Clin. Oncol. 12, 1137-1149 (1994).
66. Singer S, Corson JM, Demetri GD, Healey EA, Marcus K, Eberlein TJ. Prognostic factors predictive of survival for truncal and retroperitoneal soft-tissue sarcoma. Ann. Surg. 221, 185-195 (1995).
67. Hensley ML, Ishill N, Soslow R et al. Adjuvant gemcitabine plus docetaxel for completely resected stages I-IV high grade uterine leiomyosarcoma: results of a prospective study. Gynecol. Oncol. 112, 563-567 (2009).
68. Ferrari A, Gronchi A, Casanova M et al. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer 101, 627-634 (2004).
69. Eilber FC, Brennan MF, Eilber FR et al. Chemotherapy is associated with improved survival in adult patients with primary extremity synovial sarcoma. Ann. Surg. 246, 105-113 (2007).
70. Eilber FC, Eilber FR, Eckardt J et al. The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma. Ann. Surg. 240, 686-695 (2004).
71. Cormier JN, Huang X, Xing Y et al. Cohort analysis of patients with localized, high-risk, extremity soft tissue sarcoma treated at two cancer centers: chemotherapy-associated outcomes. J. Clin. Oncol. 22, 4567-4574 (2004).
72. Figueredo A, Bramwell VH, Bell R, Davis AM, Charette ML; The Cancer Care Ontario Practice Guidelines Initiative Sarcoma Disease Site Group. Adjuvant chemotherapy following complete resection of soft tissue sarcoma in adults: a clinical practice guideline. Sarcoma 6, 5-18 (2002).
73. Eilber FC, Rosen G, Eckardt J et al. Treatment-induced pathologic necrosis: a predictor of local recurrence and survival in patients receiving neoadjuvant therapy for high-grade extremity soft tissue sarcomas. J. Clin. Oncol. 19, 3203-3209 (2001).
74. Meric F, Hess KR, Varma DG et al. Radiographic response to neoadjuvant chemotherapy is a predictor of local control and survival in soft tissue sarcomas. Cancer 95, 1120-1126 (2002).
75. Pisters PW, Patel SR, Varma DG et al. Preoperative chemotherapy for stage IIIB extremity soft tissue sarcoma: long-term results from a single institution. J. Clin. Oncol. 15, 3481-3487 (1997).
76. Hohenberger P, Wysocki WM. Neoadjuvant treatment of locally advanced soft tissue sarcoma of the limbs: which treatment to choose? Oncologist 13, 175-186 (2008).
77. Gortzak E, Azzarelli A, Buesa J et al. A randomised Phase II study on neoadjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. Eur. J. Cancer 37, 1096-1103 (2001).
78. Grobmyer SR, Maki RG, Demetri GD et al. Neo-adjuvant chemotherapy for primary high-grade extremity soft tissue sarcoma. Ann. Oncol. 15, 1667-1672 (2004).
79. Esiashvili N, Goodman M, Marcus RB Jr. Changes in incidence and survival of Ewing sarcoma patients over the past 3 decades: Surveillance Epidemiology and End Results data. J. Pediatr. Hematol. Oncol. 30, 425-430 (2008).
80. Punyko JA, Mertens AC, Baker KS, Ness KK, Robison LL, Gurney JG. Long-term survival probabilities for childhood rhabdomyosarcoma. A population-based evaluation. Cancer 103, 1475-1483 (2005).
81. Bacci G, Balladelli A, Forni C et al. Adjuvant and neoadjuvant chemotherapy for Ewing sarcoma family tumors in patients aged between 40 and 60: report of 35 cases and comparison of results with 586 younger patients treated with the same protocols in the same years. Cancer 109, 780-786 (2007).
82. Ferrari A, Dileo P, Casanova M et al. Rhabdomyosarcoma in adults. A retrospective analysis of 171 patients treated at a single institution. Cancer 98, 571-580 (2003).
83. Raney RB, Asmar L, Newton WA Jr et al. Ewing's sarcoma of soft tissues in childhood: a report from the Intergroup Rhabdomyosarcoma study, 1972 to 1991. J. Clin. Oncol. 15, 574-582 (1997).
84. Nesbit ME Jr, Gehan EA, Burgert EO Jr et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the First Intergroup study. J. Clin. Oncol. 8, 1664-1674 (1990). • Demonstration of superiority of the four-drug combination (containing doxorubicin) versus the three-drug combination for the adjuvant management of Ewing's sarcoma (ES).
85. Burgert EO Jr, Nesbit ME, Garnsey LA et al. Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: intergroup study IESS-II. J. Clin. Oncol. 8, 1514-1524 (1990). • Demonstration of the value of high-dose doxorubicin for the adjuvant management of ES.
86. Grier HE, Krailo MD, Tarbell NJ et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N. Engl. J. Med. 348, 694-701 (2003).
87. Craft A, Cotterill S, Malcolm A et al. Ifosfamide-containing chemotherapy in Ewing's sarcoma: the second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor study. J. Clin. Oncol. 16, 3628-3633 (1998). • First study to demonstrate the value of adjuvant ifosfamide to the management of ES.
88. Paulussen M, Ahrens S, Dunst J et al. Localized Ewing tumor of bone: final results of the cooperative Ewing's Sarcoma Study CESS 86. J. Clin. Oncol. 19, 1818-1829 (2001).
89. Paulussen M, Craft AW, Lewis I et al. Results of the EICESS-92 study: two randomized trials of Ewing's sarcoma treatment - cyclophosphamide compared with ifosfamide in standard-risk patients and assessment of benefit of etoposide added to standard treatment in high-risk patients. J. Clin. Oncol. 26, 4385-4393 (2008).
90. Kolb EA, Kushner BH, Gorlick R et al. Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults. J. Clin. Oncol. 21, 3423-3430 (2003). •• Established the ifosfamide-etoposide/ vincristine-doxorubicin- cyclophosphamide regimen as the current standard of care outside clinical trials in the management of ES.
91. Paulussen M, Ahrens S, Craft AW et al. Ewing's tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients. J. Clin. Oncol. 16, 3044-3052 (1998).
92. Pinkerton CR, Bataillard A, Guillo S, Oberlin O, Fervers B, Philip T. Treatment strategies for metastatic Ewing's sarcoma. Eur. J. Cancer 37, 1338-1344 (2001).
93. Kushner BH, Meyers PA, Gerald WL et al. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults. J. Clin. Oncol. 13, 2796-2804 (1995).
94. Womer RB, Daller RT, Fenton JG, Miser JS. Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing's sarcomas and soft tissue sarcomas in children. Eur. J. Cancer 36, 87-94 (2000).
95. Perentesis J, Katsanis E, DeFor T, Neglia J, Ramsay N. Autologous stem cell transplantation for high-risk pediatric solid tumors. Bone Marrow Transplant. 24, 609-615 (1999).
96. Laurence V, Pierga JY, Barthier S et al. Long-term follow up of high-dose chemotherapy with autologous stem cell rescue in adults with Ewing tumor. Am. J. Clin. Oncol. 28, 301-309 (2005).
97. Kushner BH, Meyers PA. How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review. J. Clin. Oncol. 19, 870-880 (2001).
98. Maurer HM, Beltangady M, Gehan EA et al. The Intergroup Rhabdomyosarcoma Study-I. A final report. Cancer 61, 209-220 (1988). •• Reposts the three-drug combinational chemotherapy (vincristine-actinomycin D-cyclophosohamide) is considered as the gold standard, both in the adjuvant and in the metastatic setting. The application of multiple-drug combinations does not offer any further survival benefit.
99. Maurer HM, Gehan EA, Beltangady M et al. The Intergroup Rhabdomyosarcoma study-II. Cancer 71, 1904-1922 (1993).
100. Crist W, Gehan EA, Ragab AH et al. The Third Intergroup Rhabdomyosarcoma study. J. Clin. Oncol. 13, 610-630 (1995). • For patients with low-risk tumours at favored sites, the vincristine-actinomycin D combination is sufficient as adjuvant chemotherapy.
101. Crist WM, Anderson JR, Meza JL et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. J. Clin. Oncol. 19, 3091-3102 (2001).
102. Breneman JC, Lyden E, Pappo AS et al. Prognostic factors and clinical outcomes in children and adolescents with metastatic rhabdomyosarcoma - a report from the Intergroup Rhabdomyosarcoma study IV. J. Clin. Oncol. 21, 78-84 (2003).
103. Little DJ, Ballo MT, Zagars GK et al. Adult rhabdomyosarcoma: outcome following multimodality treatment. Cancer 95, 377-388 (2002).
104. Baker KS, Anderson JR, Link MP et al. Benefit of intensified therapy for patients with local or regional embryonal rhabdomyosarcoma: results from the Intergroup Rhabdomyosarcoma study IV. J. Clin. Oncol. 18, 2427-2434 (2000).
105. Weigel BJ, Breitfeld PP, Hawkins D, Crist WM, Baker KS. Role of high-dose chemotherapy with hematopoietic stem cell rescue in the treatment of metastatic or recurrent rhabdomyosarcoma. J. Pediatr. Hematol. Oncol. 23, 272-276 (2001).